Nilotinib revisited in GIST: Salvage use in patients with severe imatinib toxicity
Johanna Falkenhorst, Peter Hohenberger, Giorgia Mancino, Andrea Scrima et autres
de (code pays fourni par la source)
0 citations
The Oncologist
Thomas Mühlenberg
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
91Publications signalées
1153Citations signalées
9Affiliations récentes
Les institutions déclarées
Les domaines associés
Gastrointestinal Tumor Research and TreatmentGastric Cancer Management and OutcomesSarcoma Diagnosis and TreatmentPeptidase Inhibition and AnalysisChronic Myeloid Leukemia Treatments
Les publications récentes
Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST
Tom Schulz, Maria Beerbaum, Andrea Scrima, H. Jantzen et autres
us, de (code pays fourni par la source)
0 citations
Nature Communications
Structural rearrangement in the binding pocket of KIT/PDGFRA revealed by covalent targeting of the DFG-1 Cysteine
Giorgia Mancino, Andrea Scrima, Tom Schulz, Alina Teuber et autres
de, us (code pays fourni par la source)
0 citations
ChemRxiv
Done EAZY: An Automated Procedure for 89Zr-Radiolabeling and Size-Exclusion Chromatography Purification of Nanoliposomal Anticancer Therapeutics
Justin Dubbert, F. Kunkel, Thomas Mühlenberg, Susanne Grunewald et autres
de, us (code pays fourni par la source)
0 citations
Molecular Pharmaceutics
Quantifying Treatment Resistance in Mixtures of Gastrointestinal Stromal Tumor Cells with BARMIX
Mohammad Darbalaei, Thomas Mühlenberg, Julia Zummack, Philip Dujardin et autres
de (code pays fourni par la source)
0 citations
bioRxiv (Cold Spring Harbor Laboratory)
Structure-based Scaffold Hopping Reveals Strategies to Overcome Oncogenic KIT and PDGFRA Mutation-Driven Drug-Resistance in GIST
Tom Schulz, Maria Beerbaum, Andrea Scrima, Hannah Jantzen et autres
de (code pays fourni par la source)
0 citations
Research Square
Supplementary Figure S2 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz, Rainer Hamacher et autres
0 citations
Supplementary Table S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz, Rainer Hamacher et autres
0 citations
Supplementary Table S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz, Rainer Hamacher et autres
0 citations
Data from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz, Rainer Hamacher et autres
0 citations
Supplementary Figure S1 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz, Rainer Hamacher et autres
0 citations
Supplementary Table S4 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)
Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz, Rainer Hamacher et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.